AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34437752
Drug: REGN1908-1909 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN1908-1909 (600 mg)
Trial: 34437752
Drug: REGN1908-1909 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN1908-1909 (150 mg)
Trial: 34437752
Drug: REGN1908-1909 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN1908-1909 (300 mg)
Trial: 36272526
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) with cisplatin+vinorelbine
Trial: 34327047
Drug: First-line therapies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line therapies for POTS
Trial: 34327047
Drug: Second-line therapies
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapies for POTS
Trial: 34327047
Drug: Third-line therapies
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-line therapies for POTS
Trial: 32993879
Drug: Ultra‐lose dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra‐lose dose imaging protocol (ULDP)
Trial: 32993879
Drug: Standard low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard low‐dose imaging protocol (LDP)
Trial: 32329435
Drug: Zolpidem extended-release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem extended-release
Trial: 35218300
Drug: Immediate antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antiretroviral therapy (ART) offered through trial clinics
Trial: 33221932
Drug: MDMA-assisted psychotherapy
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted psychotherapy (75–125 mg) in non-taper group
Trial: 33221932
Drug: MDMA-assisted psychotherapy
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted psychotherapy (75–125 mg) in taper group
Trial: 33221932
Drug: MDMA-assisted psychotherapy
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted psychotherapy (75–125 mg)
Trial: 35726101
Drug: Ultrasound-guided injections
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injections (group 2)
Trial: 35726101
Drug: Blind injections
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind injections (group 1)
Trial: 33726499
Drug: pUDK‐HGF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pUDK‐HGF treatment (intramuscular injection on days 0, 14, and 28)
Trial: 33726499
Drug: pUDK‐HGF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pUDK‐HGF treatment
Trial: 36069821
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (taxane and anthracycline-based) with investigational agents
Trial: 36069821
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (taxane and anthracycline-based) without investigational agents
Trial: 33982806
Drug: IFN-α-2b aerosol
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α-2b aerosol inhalation (5,000,000 U twice daily)
Trial: 33982806
Drug: IFN-α-2b therapy
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α-2b therapy
Trial: 33982806
Drug: IFN-α-2b treatment
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α-2b treatment 0–2 days after symptom onset
Trial: 33982806
Drug: IFN-α-2b treatment
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α-2b treatment 3–5 days after symptom onset
Trial: 33982806
Drug: IFN-α-2b treatment
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α-2b treatment 6–8 days after symptom onset
Trial: 33091354
Drug: Blood transfusion
RxNorm normalized name: Blood transfusion, auxiliary products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood transfusion (whole blood at a target volume of 20 mL per kg)
Trial: 32740950
Drug: Partially hydrolyzed
RxNorm normalized name: Human Skin Proteins, Partially Hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolyzed guar gum (PHGG) 10 g twice daily for 14 days prior and 14 days during pelvic radiation
Trial: 34937821
Drug: High-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose heparin (HH) receiving an initial heparin dose of 450 u/kg
Trial: 34937821
Drug: Heparin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin concentration monitoring (HC) with Hepcon HMS
Trial: 34937821
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving a standard heparin dose of 300 u/kg
Trial: 36239038
Drug: Zavegepant 10
RxNorm normalized name: zavegepant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zavegepant 10 mg
Trial: 36239038
Drug: Zavegepant 20
RxNorm normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zavegepant 20 mg
Trial: 36239038
Drug: Zavegepant 5
RxNorm normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zavegepant 5 mg
Trial: 36599584
Drug: 1-month DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month DAPT followed by clopidogrel monotherapy
Trial: 32684537
Drug: 3-month DAPT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month DAPT followed by aspirin monotherapy
Trial: 32843081
Drug: Dutogliptin plus
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutogliptin plus filgrastim (G-CSF)
Trial: 33183672
Drug: F(ab')2 antivenom
RxNorm normalized name: Crotalidae immune F(ab')2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F(ab')2 antivenom therapy plus local cryotherapy
Trial: 33183672
Drug: F(ab')2 antivenom
RxNorm normalized name: Crotalidae immune F(ab')2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F(ab')2 antivenom therapy
Trial: 35652703
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment + escitalopram
Trial: 35652703
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment + pramipexole
Trial: 35652703
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment + transcranial magnetic stimulation (TMS)
Trial: 32871701
Drug: Family‐Focused Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐Focused Treatment for Childhood Depression (FFT‐CD)
Trial: 33726804
Drug: Enzalutamide (Xtandi®)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (Xtandi®) 160 mg (4x40 mg) daily for five consecutive days
Trial: 33726804
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment for patients hospitalised with COVID‐19
Trial: 32875505
Drug: Integrated clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated clinical prediction rule (iCPR) system for antibiotic prescribing in ARIs
Trial: 33664429
Drug: MK-7 375
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 375 µg daily
Trial: 32049562
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (30 maximum inspirations at 50% PImax, twice per day, 6 days per week)
Trial: 35357564
Drug: OFF medication
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFF medication (PD patients)
Trial: 32717926
Drug: Ethanol consumption
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol consumption (35 g daily for eight weeks)
Trial: 33687323
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBTi) and manual standardized stress acupuncture (MSSA)
Trial: 33687323
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBTi) only
Trial: 32471328
Drug: Control (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (not using oral contraceptives)
Trial: 36216658
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 or 200 mg daily plus best supportive care (BSC)
Trial: 34096641
Drug: Parent-led cognitive
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-led cognitive behavioural therapy (From Timid to Tiger), 8 sessions
Trial: 36256505
Drug: CC-90001 (10–720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90001 (10–720 mg single dose or 30–480 mg once daily for 7–18 days)
Trial: 36256505
Drug: CC-90001
RxNorm normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90001
Trial: 33971928
Drug: Music exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music exercise therapy
Trial: 33971928
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation therapies
Trial: 35962638
Drug: 3 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 µg/kg of intranasal desmopressin acetate
Trial: 35962638
Drug: 1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL/kg of intranasal sodium chloride 0.65% (placebo)
Trial: 33065164
Drug: Prognostic model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic model for predicting deterioration in health-related quality of life (dHRQoL) based on 12/87 selected variables related to chronic conditions, medication, functional status, well-being, and HRQoL.
Trial: 32817632
Drug: 12% N,N‐diethylbenzamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% N,N‐diethylbenzamide w/w cream distributed by village health volunteers (VHVs)
Trial: 37340514
Drug: Intralesional autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional autologous PRP plus classic topical treatment
Trial: 37340514
Drug: Topical compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical compounds only
Trial: 33511686
Drug: Tocilizumab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (single infusion)
Trial: 36117310
Drug: Systemic inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic inflammation (SI) with LPS injections (1 ng/kg and 0.5 ng/kg)
Trial: 33534818
Drug: Combined protocol
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined protocol using an optimised MUAC-based dose of ready-to-use therapeutic food (RUTF)
Trial: 33422245
Drug: Bio‐Manguinhos‐Fiocruz standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Manguinhos‐Fiocruz standard dose
Trial: 33422245
Drug: Bio‐Manguinhos‐Fiocruz fractional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Manguinhos‐Fiocruz fractional dose
Trial: 33422245
Drug: Chumakov Institute
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chumakov Institute of Poliomyelitis and Viral Encephalitides standard dose
Trial: 33422245
Drug: Chumakov Institute
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chumakov Institute of Poliomyelitis and Viral Encephalitides fractional dose
Trial: 33422245
Drug: Institut Pasteur
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institut Pasteur Dakar standard dose
Trial: 33422245
Drug: Institut Pasteur
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institut Pasteur Dakar fractional dose
Trial: 33422245
Drug: Sanofi Pasteur
RxNorm normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanofi Pasteur standard dose
Trial: 33422245
Drug: Sanofi Pasteur
RxNorm normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanofi Pasteur fractional dose
Trial: 34059348
Drug: Intervention (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (3 standardized CBT‐based sessions in the 6–12 weeks post‐chemotherapy)
Trial: 32321161
Drug: High Breakfast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Breakfast (HBR) group, n=12, protein intake at breakfast: 0.33 g/kg BW, lunch: 0.46 g/kg BW, dinner: 0.48 g/kg BW, total daily protein intake: 1.30 g/kg BW/d
Trial: 32321161
Drug: Low Breakfast
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Breakfast (LBR) group, n=14, protein intake at breakfast: 0.12 g/kg BW, lunch: 0.45 g/kg BW, dinner: 0.83 g/kg BW, total daily protein intake: 1.30 g/kg BW/d
Trial: 38664701
Drug: Standard pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmaceutical care
Trial: 34656876
Drug: Aviandr 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aviandr 40 mg daily
Trial: 34656876
Drug: Aviandr 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aviandr 60 mg daily
Trial: 34656876
Drug: Aviandr (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aviandr (both doses)
Trial: 34783456
Drug: Generic budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Generic budesonide nasal spray (256 μg)
Trial: 34783456
Drug: Branded budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Branded budesonide nasal spray (256 μg)
Trial: 34074263
Drug: Randomized test‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized test‐treatment studies
Trial: 34074263
Drug: Adaptive designs
RxNorm normalized name: Designer Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive designs within randomized test‐treatment studies
Trial: 32762394
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid treatment
Trial: 32492377
Drug: CSP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSP with submucosal injection (CSP-SI)
Trial: 33026895
Drug: Control (FES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (FES treatment and conventional physical therapy)
Trial: 34979180
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (n = 318)
Trial: 36107590
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg/kg) intramuscularly injected 30 minutes before general anesthesia
Trial: 32971314
Drug: Continuation cognitive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation cognitive therapy (CT)
Trial: 32967726
Drug: Electrolyte supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte supplementation (Magnesium, Calcium, and Potassium) with intravenous normal saline
Trial: 36263238
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 0.6 mg/kg rocuronium based on Total Body Weight (TBW) in Group 1K
Trial: 35570929
Drug: Avelumab maintenance
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab maintenance therapy (AVE group)
Trial: 33748529
Drug: Control mattress
RxNorm normalized name: PADS,MATTRESS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control mattress (treatment as usual; TAU): non‐oscillating hospital‐crib mattress
Trial: 33748529
Drug: Control mattress
RxNorm normalized name: PADS,MATTRESS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control mattress (treatment as usual; TAU)
Trial: 32595082
Drug: Antipsychotic polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic polypharmacy (two or more co-prescribed antipsychotic drugs)
Trial: 35253776
Drug: Structured Medication
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Medication Review (SMR)
Trial: 38231511
Drug: Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Medication Management (MEDS)
Trial: 33092897
Drug: Wii training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wii training in addition to traditional therapy
Trial: 33109663
Drug: Iodinated oil
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodinated oil injection (OSCM group, oil-soluble contrast media)
Trial: 33109663
Drug: Ioversol injection
RxNorm normalized name: Ioversol
DrugBank: Ioversol (DB09134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ioversol injection (WSCM group, water-soluble contrast media)
Trial: 33109663
Drug: Iodinated oil
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodinated oil injection (OSCM group)
Trial: 35215501
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements based on L-Theanine and Vitamin B6
Trial: 35073989
Drug: 1 +
RxNorm normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 + 1 schedule (one dose at 6 weeks and a booster at 9 months)
Trial: 35073989
Drug: 3 +
RxNorm normalized name: D3 + K2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 + 0 schedule (three doses at 6, 10, and 14 weeks)
Trial: 33783399
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 36 IU (3 sprays) twice a day
Trial: 33783399
Drug: Intranasal placebo-oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo-oxytocin (3 sprays) twice a day
Trial: 34481326
Drug: Oxytocin (OT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (OT) nasal spray
Trial: 32750332
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) nasal spray
Trial: 32926462
Drug: Baricitinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (2 mg)
Trial: 34032934
Drug: Personalized pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Personalized pharmaceutical plan with a 30-min opioid-targeted pharmaceutical interview
Trial: 35538479
Drug: E2/NOMAC (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NOMAC (1.5 mg 17β-estradiol + 2.5 mg nomegestrol acetate)
Trial: 35538479
Drug: DNG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNG (2 mg/daily dienogest)
Trial: 32101302
Drug: Skin Self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin Self-monitoring (SSM) smartphone application with monthly self-monitoring reminders
Trial: 32739072
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene program combined with home-phone health promoting counseling
Trial: 35740202
Drug: Ivermectin (400–600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (400–600 µg/kg/d)
Trial: 36267612
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hyperbaric bupivacaine (0.5%)
Trial: 36267612
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of hyperbaric bupivacaine (0.5%)
Trial: 33597131
Drug: ACC/AHA 2017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC/AHA 2017 guideline recommendation for antihypertensive medication
Trial: 33597131
Drug: JNC7 guideline
RxNorm normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNC7 guideline recommendation for antihypertensive medication